Veradermics, Incorporated MANE
Updated: 18 Jun 2026
No signal published yet
We already track Veradermics and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Veradermics, Incorporated? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Veradermics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
In May 2026, Veradermics reported positive topline results from its Phase 2/3 '302' study, showing that VDPHL01 achieved significant hair growth in male patients with a favorable safety profile. The company also completed an upsized financing in April 2026, raising approximately $766.8 million in gross proceeds to support its clinical programs through 2030.
What Firelda Watch includes for Veradermics, Incorporated
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Veradermics, Incorporated? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Veradermics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more